Although COVID-19 has been linked to worse acute outcomes in patients with some neurodegenerative disorders, its long-term impact on dementia remains unclear.
Objective
To investigate the outcomes of COVID-19 survivors with dementia.
Methods
This retrospective study evaluated 9806 patients with dementia in the Montefiore Health System (January 2016 to July 2023). Comparisons were made between dementia patients with and without a positive SARS-CoV-2 polymerase-chain-reaction test who had a follow-up at least two weeks post-infection. Outcomes included all-cause mortality, major adverse cardiovascular events (MACE), new-onset dysphagia, dyspnea, fatigue, new-onset sleep disturbances, altered mental status, first-time fall, headache, new-onset depression, and new-onset anxiety. Adjusted hazard ratios (aHR) were computed adjusting for age, sex, race, ethnicity, and pre-existing comorbidities.
Results
Dementia patients with COVID-19 were younger, more likely to be male, and had a higher prevalence of major pre-existing comorbidities compared to those without COVID-19. Patients who survived acute COVID-19 were more likely to die than non-COVID controls after adjusting for covariates (aHR = 1.65 [1.43, 1.91]). COVID-19 was significantly associated with higher risk of MACE (aHR = 1.58 [1.41, 1.78]), new-onset dysphagia (aHR = 1.64 [1.42, 1.91]), dyspnea (aHR = 1.27 [1.12, 1.44]), fatigue (aHR = 1.42 [1.22, 1.65]), new-onset sleep disturbances (aHR = 1.36 [1.15, 1.60]), altered mental status (aHR = 1.36 [1.16, 1.59]), and first-time fall (aHR = 1.34 [1.09, 1.65]).
Conclusions
COVID-19 increases the risk of mortality and other adverse health outcomes in dementia patients. These findings highlight the need for closer follow-up and management strategies for dementia patients post-COVID-19.
GreenhalghTSivanMPerlowskiA, et al.Long COVID: a clinical update. Lancet2024; 404: 707–724.
2.
LengFHinzRGentlemanS, et al.Neuroinflammation is independently associated with brain network dysfunction in Alzheimer's disease. Mol Psychiatry2023; 28: 1303–1311.
3.
GreeneCConnollyRBrennanD, et al.Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nat Neurosci2024; 27: 421–432.
4.
WangXCuiLJiX. Cognitive impairment caused by hypoxia: from clinical evidences to molecular mechanisms. Metab Brain Dis2022; 37: 51–66.
5.
LallRMohammedROjhaU. What are the links between hypoxia and Alzheimer's disease?Neuropsychiatr Dis Treat2019; 15: 1343–1354.
6.
BurtscherJMalletRTBurtscherM, et al.Hypoxia and brain aging: neurodegeneration or neuroprotection?Ageing Res Rev2021; 68: 101343.
7.
HambaliAKumarJHashimNFM, et al.Hypoxia-induced neuroinflammation in Alzheimer's disease: potential neuroprotective effects of Centella asiatica. Front Physiol2021; 12: 712317.
8.
RanucciMBaryshnikovaEAnguissolaM, et al.The long term residual effects of COVID-associated coagulopathy. Int J Mol Sci2023; 24: 5514.
9.
SeighaliNAbdollahiAShafieeA, et al.The global prevalence of depression, anxiety, and sleep disorder among patients coping with post COVID-19 syndrome (long COVID): a systematic review and meta-analysis. BMC Psychiatry2024; 24: 105.
10.
SoysalPSmithL. The prevalence and co-existence of geriatric syndromes in older patients with dementia compared to those without dementia. Aging Clin Exp Res2024; 36: 66.
11.
DavisHEMcCorkellLVogelJM, et al.Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol2023; 21: 133–146.
12.
Estupinan ArtilesCReganJDonnellanC. Physiological mechanisms and associated pathophysiology of dysphagia in older adults. Gerontol Geriatr Med2022; 8: 23337214221142949.
13.
ZhangLWangJDoveA, et al.Injurious falls before, during and after dementia diagnosis: a population-based study. Age Ageing2022; 51: afac299.
14.
BianchettiARozziniRGueriniF, et al.Clinical presentation of COVID19 in dementia patients. J Nutr Health Aging2020; 24: 560–562.
15.
FongTGInouyeSK. The inter-relationship between delirium and dementia: the importance of delirium prevention. Nat Rev Neurol2022; 18: 579–596.
16.
InouyeSK. Delirium in older persons. N Engl J Med2006; 354: 1157–1165.
17.
XieYXuEBoweB, et al.Long-term cardiovascular outcomes of COVID-19. Nat Med2022; 28: 583–590.
18.
DubeySDasSGhoshR, et al.The effects of SARS-CoV-2 infection on the cognitive functioning of patients with pre-existing dementia. J Alzheimers Dis Rep2023; 7: 119–128.
19.
HwangJMKimJHParkJS, et al.Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study. Neurol Sci2020; 41: 2317–2324.
20.
MayerCWooMSBrehmTT, et al.History of cerebrovascular disease but not dementia increases the risk for secondary vascular events during SARS-CoV-2 infection with presumed Omicron variant: a retrospective observational study. Eur J Neurol2023; 30: 2297–2304.
21.
EtemadifarMAbhariAPNouriH, et al.Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study. BMC Neurol2022; 22: 64.
22.
BabtainFBajafarANazmiO, et al.The disease course of multiple sclerosis before and during COVID-19 pandemic: a retrospective five-year study. Mult Scler Relat Disord2022; 65: 103985.
23.
EtemadifarMSedaghatNAghababaeeA, et al.COVID-19 and the risk of relapse in multiple sclerosis patients: a fight with no bystander effect?Mult Scler Relat Disord2021; 51: 102915.
24.
VercellinoMBosaCAltenoA, et al.SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in multiple sclerosis: a propensity score matched case-control study. Mult Scler Relat Disord2023; 74: 104715.
25.
MontiniFNozzolilloATedoneN, et al.COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: a 2-year study. J Neurol Neurosurg Psychiatry2024; 95: 342–347.
26.
BstehGAssarHGradlC, et al.Long-term outcome after COVID-19 infection in multiple sclerosis: a nation-wide multicenter matched-control study. Eur J Neurol2022; 29: 3050–3060.
27.
AndersenMLZegersFDJolvingLR, et al.Patients with multiple sclerosis: COVID-19 related disease activity and hospitalisations based on a nationwide cohort study. Mult Scler Relat Disord2023; 79: 105031.
28.
RahmaniMMoghadasiANShahiS, et al.COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: a case-control study. Med Clin (Barc)2023; 160: 187–192.
29.
PeetersGVan RemoortelANagelsG, et al.Occurrence and severity of coronavirus disease 2019 are associated with clinical disability worsening in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2023; 10: e200089.
30.
ConwaySEHealyBCZurawskiJ, et al.COVID-19 severity is associated with worsened neurological outcomes in multiple sclerosis and related disorders. Mult Scler Relat Disord2022; 63: 103946.
31.
HadidchiRWangSHRezkoD, et al.SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population. Mult Scler Relat Disord2024; 86: 105613.
32.
AntoniniALetaVTeoJ, et al.Outcome of Parkinson's disease patients affected by COVID-19. Mov Disord2020; 35: 905–908.
33.
GouseBMSpearsWENieves ArchibaldA, et al.Catatonia in a hospitalized patient with COVID-19 and proposed immune-mediated mechanism. Brain Behav Immun2020; 89: 529–530.
34.
Al-KuraishyHMAl-GareebAIKaushikA, et al.SARS-COV-2 infection and Parkinson's disease: possible links and perspectives. J Neurosci Res2023; 101: 952–975.
35.
AmrutaNChastainWHPazM, et al.SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders. Cytokine Growth Factor Rev2021; 58: 1–15.
36.
HadidchiRAl-AniYPiskunH, et al.Long-term outcomes of patients with Parkinson’s disease 3.5 years post SARS-CoV-2 infection in an inner-city population in the Bronx. Res Sq2024. DOI: https://doi.org/10.21203/rs.3.rs-4373059/v1[Preprint]. Posted May 28, 2024.
37.
KiniACaoDNardinM, et al.Types of myocardial injury and mid-term outcomes in patients with COVID-19. Eur Heart J Qual Care Clin Outcomes2021; 7: 438–446.
38.
ReyesLFGarcia-GalloEMurthyS, et al.Major adverse cardiovascular events (MACE) in patients with severe COVID-19 registered in the ISARIC WHO clinical characterization protocol: a prospective, multinational, observational study. J Crit Care2023; 77: 154318.
39.
LuJYHouWDuongTQ. Longitudinal prediction of hospital-acquired acute kidney injury in COVID-19: a two-center study. Infection2022; 50: 109–119.
40.
LuJYHoSLBuczekA, et al.Clinical predictors of recovery of COVID-19 associated-abnormal liver function test 2 months after hospital discharge. Sci Rep2022; 12: 17972.
41.
LuJYBoparaiMSShiC, et al.Long-term outcomes of COVID-19 survivors with hospital AKI: association with time to recovery from AKI. Nephrol Dial Transplant2023; 38: 2160–2169.
42.
Dell'AquilaKLeeJWangSH, et al.Incidence, characteristics, risk factors and outcomes of diabetic ketoacidosis in COVID-19 patients: comparison with influenza and pre-pandemic data. Diabetes Obes Metab2023; 25: 2482–2494.
43.
FeitAGordonMAlamuriTT, et al.Long-term clinical outcomes and healthcare utilization of sickle cell disease patients with COVID-19: a 2.5-year follow-up study. Eur J Haematol2023; 111: 636–643.
44.
EligulashviliADarrellMMillerC, et al.COVID-19 Patients in the COVID-19 recovery and engagement (CORE) clinics in the Bronx. Diagnostics (Basel)2022; 13: 119.
45.
LuJYBuczekAFleysherR, et al.Characteristics of COVID-19 patients with multiorgan injury across the pandemic in a large academic health system in the Bronx, New York. Heliyon2023; 9: e15277.
46.
LuJYBuczekAFleysherR, et al.Outcomes of hospitalized patients with COVID-19 with acute kidney injury and acute cardiac injury. Front Cardiovasc Med2021; 8: 798897.
47.
EligulashviliAGordonMLeeJS, et al.Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment. PLoS Med2024; 21: e1004263.
48.
EligulashviliADarrellMGordonM, et al.Patients with unmet social needs are at higher risks of developing severe long COVID-19 symptoms and neuropsychiatric sequela. Sci Rep2024; 14: 7743.
ZhangZ. Survival analysis in the presence of competing risks. Ann Transl Med2017; 5: 47.
51.
MiraAGoncalvesRRodriguesIT. Dysphagia in Alzheimer's disease: a systematic review. Dement Neuropsychol2022; 16: 261–269.
52.
ShenkerJISinghG. Sleep and dementia. Mo Med2017; 114: 311–315.
53.
van DoornCGruber-BaldiniALZimmermanS, et al.Dementia as a risk factor for falls and fall injuries among nursing home residents. J Am Geriatr Soc2003; 51: 1213–1218.
54.
LuceyBP. It's complicated: the relationship between sleep and Alzheimer's disease in humans. Neurobiol Dis2020; 144: 105031.
55.
CecchettoAGuarnieriGTorreggianiG, et al.Dyspnea in post-acute COVID-19: a multi-parametric cardiopulmonary evaluation. J Clin Med2023; 12: 4658.
56.
SandlerCXWyllerVBBMoss-MorrisR, et al.Long COVID and post-infective fatigue syndrome: a review. Open Forum Infect Dis2021; 8: ofab440.
57.
NguyenKHBaoYMortazaviJ, et al.Prevalence and factors associated with long COVID symptoms among U.S. Adults, 2022. Vaccines (Basel)2024; 12: 99.
58.
AntonielloDMilsteinMJDardickJ, et al.Altered mental status in COVID-19. J Neurol2022; 269: 12–18.
59.
Pena-OrbeaCLapinBLiY, et al.Sleep disturbance severity and correlates in post-acute sequelae of COVID-19 (PASC). J Gen Intern Med2023; 38: 2015–2017.
60.
SirohiyaPElavarasiASagirajuHKR, et al.Silent hypoxia in coronavirus disease-2019: is it more dangerous? -A retrospective cohort study. Lung India2022; 39: 247–253.
61.
OwensCDBonin PintoCMukliP, et al.Vascular mechanisms leading to progression of mild cognitive impairment to dementia after COVID-19: protocol and methodology of a prospective longitudinal observational study. PLoS One2023; 18: e0289508.
62.
Hernandez-ParraHReyes-HernandezODFigueroa-GonzalezG, et al.Alteration of the blood-brain barrier by COVID-19 and its implication in the permeation of drugs into the brain. Front Cell Neurosci2023; 17: 1125109.
63.
CiaccioMLo SassoBScazzoneC, et al.COVID-19 and Alzheimer's disease. Brain Sci2021; 11: 305.
64.
SiegmundLADistelhorstKSBenaJF, et al.Relationships between physical activity, social isolation, and depression among older adults during COVID-19: a path analysis. Geriatr Nurs2021; 42: 1240–1244.
65.
ZhangWXiaoDMaoQ, et al.Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther2023; 8: 267.
66.
SantiagoJAQuinnJPPotashkinJA. Physical activity rewires the human brain against neurodegeneration. Int J Mol Sci2022; 23: 6223.
67.
BarisanoGMontagneAKislerK, et al.Blood-brain barrier link to human cognitive impairment and Alzheimer's disease. Nat Cardiovasc Res2022; 1: 108–115.
68.
BeamCRKaneshiroCJangJY, et al.Differences between women and men in incidence rates of dementia and Alzheimer's disease. J Alzheimers Dis2018; 64: 1077–1083.
69.
FabiaoJSassiBPedrolloEF, et al.Why do men have worse COVID-19-related outcomes? A systematic review and meta-analysis with sex adjusted for age. Braz J Med Biol Res2022; 55: e11711.
70.
ZaherKBasingabFAlrahimiJ, et al.Gender differences in response to COVID-19 infection and vaccination. Biomedicines2023; 11: 1677.
71.
PeckhamHde GruijterNMRaineC, et al.Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun2020; 11: 6317.
72.
KharroubiSADiab-El-HarakeM. Sex-differences in COVID-19 diagnosis, risk factors and disease comorbidities: a large US-based cohort study. Front Public Health2022; 10: 1029190.
73.
Zafari ZangenehFSarmast ShoushtariM. Estradiol and COVID-19: does 17-estradiol have an immune-protective function in women against coronavirus?J Family Reprod Health2021; 15: 150–159.
74.
LakshmikanthTConsiglioCSardhF, et al.Immune system adaptation during gender-affirming testosterone treatment. Nature2024; 633: 155–164.
75.
BarmadaAHandfieldLFGodoy-TenaG, et al.Single-cell multi-omics analysis of COVID-19 patients with pre-existing autoimmune diseases shows aberrant immune responses to infection. Eur J Immunol2024; 54: e2350633.
76.
SimoesJLBde AraujoJBBagatiniMD. Anti-inflammatory therapy by cholinergic and purinergic modulation in multiple sclerosis associated with SARS-CoV-2 infection. Mol Neurobiol2021; 58: 5090–5111.
77.
DharraRKumar SharmaADattaS. Emerging aspects of cytokine storm in COVID-19: the role of proinflammatory cytokines and therapeutic prospects. Cytokine2023; 169: 156287.
78.
BonettoVPasettoLLisiI, et al.Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations. Front Immunol2022; 13: 1070379.
79.
Elizalde-DiazJPMiranda-NarvaezCLMartinez-LazcanoJC, et al.The relationship between chronic immune response and neurodegenerative damage in long COVID-19. Front Immunol2022; 13: 1039427.
80.
GarbuzDGZatsepinaOGEvgen'evMB. Beta amyloid, tau protein, and neuroinflammation: an attempt to integrate different hypotheses of Alzheimer's disease pathogenesis. Mol Biol (Mosk)2021; 55: 734–747.
81.
RagnoliBDa ReBGalantinoA, et al.Interrelationship between COVID-19 and coagulopathy: pathophysiological and clinical evidence. Int J Mol Sci2023; 24: 8945.
82.
SojkaMDrelich-ZbrojaAKuczynskaM, et al.Ischemic and hemorrhagic cerebrovascular events related to COVID-19 coagulopathy and hypoxemia. Int J Environ Res Public Health2022; 19: 11823.
83.
ChauhanAJWiffenLJBrownTP. COVID-19: a collision of complement, coagulation and inflammatory pathways. J Thromb Haemost2020; 18: 2110–2117.
84.
BaraleCMelchiondaEMorottiA, et al.Prothrombotic phenotype in COVID-19: focus on platelets. Int J Mol Sci2021; 22: 13638.
85.
SashindranathMNandurkarHH. Endothelial dysfunction in the brain: setting the stage for stroke and other cerebrovascular complications of COVID-19. Stroke2021; 52: 1895–1904.
86.
BakerJIncognitoAVWilsonRJA, et al.Syncope and silent hypoxemia in COVID-19: implications for the autonomic field. Auton Neurosci2021; 235: 102842.
87.
DevauxCALagierJC. Unraveling the underlying molecular mechanism of ‘silent hypoxia’ in COVID-19 patients suggests a central role for angiotensin II modulation of the AT1R-hypoxia-inducible factor signaling pathway. J Clin Med2023; 12: 2445.
88.
FavaronEInceCHiltyMP, et al.Capillary leukocytes, microaggregates, and the response to hypoxemia in the microcirculation of coronavirus disease 2019 patients. Crit Care Med2021; 49: 661–670.
89.
PoloniTEMediciVMorettiM, et al.COVID-19-related neuropathology and microglial activation in elderly with and without dementia. Brain Pathol2021; 31: e12997.
90.
ZhangFNiuLLiS, et al.Pathological impacts of chronic hypoxia on Alzheimer's disease. ACS Chem Neurosci2019; 10: 902–909.
91.
AlahmariAKrishnaGJoseAM, et al.The long-term effects of COVID-19 on pulmonary status and quality of life. PeerJ2023; 11: e16694.
92.
NaismithSLDuffySLCrossN, et al.Nocturnal hypoxemia is associated with altered parahippocampal functional brain connectivity in older adults at risk for dementia. J Alzheimers Dis2020; 73: 571–584.
93.
GuarnieriJWHaltomJAAlbrechtYES, et al.SARS-CoV-2 mitochondrial metabolic and epigenomic reprogramming in COVID-19. Pharmacol Res2024; 204: 107170.
94.
AnsoneLRoviteVBrivibaM, et al.Longitudinal NMR-based metabolomics study reveals how hospitalized COVID-19 patients recover: evidence of dyslipidemia and energy metabolism dysregulation. Int J Mol Sci2024; 25: 1523.
95.
Poblador-PlouBCalderon-LarranagaAMarta-MorenoJ, et al.Comorbidity of dementia: a cross-sectional study of primary care older patients. BMC Psychiatry2014; 14: 84.
96.
HansenMROkudaDT. Multiple sclerosis in the contemporary age: understanding the millennial patient with multiple sclerosis to create next-generation care. Neurol Clin2018; 36: 219–230.
97.
MooldijkSSLicherSWoltersFJ. Characterizing demographic, racial, and geographic diversity in dementia research: a systematic review. JAMA Neurol2021; 78: 1255–1261.
98.
Rodriguez MuruaSFarezMFQuintanaFJ. The immune response in multiple sclerosis. Annu Rev Pathol2022; 17: 121–139.
99.
MacDougallMEl-Hajj SleimanJBeaucheminP, et al.SARS-CoV-2 and multiple sclerosis: potential for disease exacerbation. Front Immunol2022; 13: 871276.
100.
Della RoccaYFonticoliLRajanTS, et al.Hypoxia: molecular pathophysiological mechanisms in human diseases. J Physiol Biochem2022; 78: 739–752.
101.
SarkarMNiranjanNBanyalPK. Mechanisms of hypoxemia. Lung India2017; 34: 47–60.
102.
DiekmanCOThomasPJWilsonCG. COVID-19 and silent hypoxemia in a minimal closed-loop model of the respiratory rhythm generator. Biol Cybern2024; 118: 145–163.
103.
AlhusainFAlromaihAAlhajressG, et al.Predictors and clinical outcomes of silent hypoxia in COVID-19 patients, a single-center retrospective cohort study. J Infect Public Health2021; 14: 1595–1599.
104.
DouaudGLeeSAlfaro-AlmagroF, et al.SARS-CoV-2 is associated with changes in brain structure in UK biobank. Nature2022; 604: 697–707.
105.
HospJAReisertMDressingA, et al.Cerebral microstructural alterations in post-COVID-condition are related to cognitive impairment, olfactory dysfunction and fatigue. Nat Commun2024; 15: 4256.
106.
WangLDavisPBKaelberDC, et al.COVID-19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021. Alzheimers Dement2023; 19: 421–432.
107.
RadomyslskyZKivitySLidarS, et al.Association between COVID-19 vaccination and critical outcomes among older adults with dementia: a comparative cohort study. Front Public Health2023; 11: 1281266.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
